A Phase 2b, Multicenter, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 08 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Obefazimod (Primary)
Indications Crohn's disease
Focus Therapeutic Use
Acronyms ENHANCE-CD
Sponsors Abivax

Most Recent Events

07 Oct 2024 According to an Abivax media release, status changed from not yet recruiting to recruiting.
07 Oct 2024 According to an Abivax media release, the first patient has been enrolled in October 2024
15 Jul 2024 According to an Abivax media release, planned start of patient enrollment anticipated in September 2024 and 12-week induction data read-out anticipated in 2H 2026.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight